A Novel Therapeutic
We’re creating the first potential treatment for Demodex blepharitis
What is TP-03?
TP-03 is a topical ophthalmic formulation of lotilaner that, if approved, may offer treatment for millions of patients with Demodex blepharitis.
Up to 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.
TP-03 may change that.
- Designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease–Demodex mite infestation
- Paralyzes and eradicates Demodex mites by selectively inhibiting parasite-specific GABA-Cl channels
- Evaluated in the pivotal Saturn-1 (Phase 2b/3) trial involving 421 patients and met all primary and secondary endpoints with no serious treatment-related adverse events and no treatment-related discontinuations
- Second pivotal Phase 3 trial, Saturn-2 underway, with results expected in Q1 2022 and the potential to be the first FDA-approved therapeutic and standard of care for the treatment of Demodex blepharitis
The active ingredient in TP-03 is lotilaner, a well-characterized anti-parasitic agent that targets parasite-specific GABA-CI channels.
Saturn-1 Phase 2b/3 Pivotal Trial
Presented by Elizabeth Yeu, MD, at ASCRS 2021 Annual Meeting.
2021 Tarsus Pharmaceuticals, Inc. All rights reserved.
TARSUS and the associated logo are trademarks of Tarsus Pharmaceuticals, Inc.
Contact Tarsus
Please reach out to us using the form below.